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São Paulo, BrazilObjectives This study sought to randomly compare cerebral protection with ANGIOGUARD (Cordis
Corporation, Bridgewater, New Jersey) with Mo.Ma (Invatec/Medtronic Vascular Inc, Santa Rosa,
California) during carotid artery stenting (CAS), using diffusion-weighted magnetic resonance imaging
(DW-MRI) to detect new ischemic cerebral lesions. The number, size, and location of lesions were
analyzed.
Background The choice of the type of cerebral protection during CAS is controversial.
Methods From July 2008 to July 2011, 60 patients undergoing CAS were randomized to
ANGIOGUARD or Mo.Ma, distributed by chance, 30 patients for each group. All patients underwent
DW-MRI before and after CAS. An independent neuroradiologist blinded to the cerebral protection
used analyzed the images. Univariate and multivariate logistic models were ﬁtted to analyze new
ischemic lesions. Alternatively, a propensity score approach was used to reduce the bias due to
differences between the groups. For the number of lesions, we used Poisson regression models.
Results New ischemic lesions seen on DW-MRI were present in 63.3% of the ANGIOGUARD group
versus 66.7% of the Mo.Ma cohort (p ¼ 0.787). The number of ischemic cerebral lesions per patient,
when present, was signiﬁcantly lower in the Mo.Ma group (a median of 6 lesions per patient vs.
a median of 10 in the ANGIOGUARD, p < 0.001). Most lesions were small (<0.5 mm) and localized in
the ipsilateral territory. One patient in the ANGIOGUARD group had a minor stroke during CAS (1.66%).
Conclusions New ischemic lesions seen on DW-MRI were present in both groups in >60%, but the
number of lesions per patient was greater in the ANGIOGUARD group. No death or disabling stroke
occurred during at least 1 year of follow-up in both cohorts. (J Am Coll Cardiol Intv 2013;6:1203–9)
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1204In recent years, carotid artery stenting (CAS) has become
an alternative to surgery, especially in high-risk patients
(1). The CREST (Carotid Revascularization Endarterec-
tomy vs. Stenting) trial (2) showed that carotid endarterec-
tomy (CEA) and CAS were comparable treatments, and the
differences between the methods (more infarction and
cranial nerve injury with CEA and increased risk of minor
ipsilateral stroke with CAS) are counterbalanced.
In the Carotid ACCULINK/ACCUNET Post Ap-
proval Trial to Uncover Unanticipated or Rare Events
(CAPTURE) registry, the authors analyzed timing, loca-
tion, severity, and types of strokes after protected CAS in
3,500 patients (3). Stroke occurred in 168 (4.8%) patients
(4% ipsilateral and 2% major stroke). The incidence of major
stroke was greater in symptomatic than in asymptomatic
patients (4.6% vs. 1.6%, respectively). This registry also
revealed that the majority of symptoms occurred during the
procedure (22.3%) or during hospitalization (57.7%), but
20% developed after discharge, aiding in the understanding
of the different mechanisms of stroke.
The use of cerebral protection devices (CPDs) duringAbbreviations
and Acronyms
CAS = carotid artery stenting
CEA = carotid
endarterectomy
CPD = cerebral protection
device
DW-MRI = diffusion-weighted
magnetic resonance imagingCAS began with Theron et al.
(4), who placed a distal balloon
occlusion system during a carotid
intervention. In a meta-analysis
comparing CAS and CEA (5),
the authors found that the CPDs
did yield signiﬁcant improve-
ments in the occurrence of dis-
abling stroke or death after CAS
in 30 days, with a lower inci-
dence in those patients with aCPD. Additionally, Bersin et al. (6), in a meta-analysis of
2,397 patients, showed that the beneﬁts of proximal CPD
extended to various subgroups of patients undergoing CAS,
including symptomatic patients and octogenarians.
In the present study, the authors aimed to compare 2
different principles of CPD during CAS, using a surrogate
imaging endpoint diffusion-weighted magnetic resonance
imaging (DW-MRI) to assess the effectiveness of the devices.
Methods
Study design and population. This was a prospective,
randomized, open-label, single-center trial in patients with
symptomatic and asymptomatic carotid stenosis who
underwent CAS with a proximal or distal CPD.
From July 2008 to July 2011, 60 patients with severe
carotid lesions (symptomatic and asymptomatic), with
indications for CAS in whom both distal ﬁlter ANGIO-
GUARD (Cordis Corporation, Bridgewater, New Jersey)
or proximal occlusion Mo.Ma Ultra (Invatec/Medtronic
Vascular Inc, Santa Rosa, California) could be used, were
selected according to the inclusion and exclusion criteria andrandomized to 1 of the CPDs. Table 1 presents the main
inclusion/exclusion criteria.
Four cervical vessels angiography performed before
randomization allowed us to classify whether patients with
tight lesions >80% had collateral circulation. When cerebral
circulation ipsilateral to the lesion was visualized during
angiography of the contralateral carotid artery, or when the
anterior communicating artery, was opaciﬁed during angi-
ography, we considered the presence of collateral circulation.
Plaque characteristics were analyzed regarding the loca-
tion, eccentricity, the presence of an ulcer, smoothness of its
surface (i.e., regular vs. irregular) eccentricity, and the degree
of calciﬁcation and tortuosity. Those patients with severe
angulation between the carotid internal artery and common
carotid artery (tortuosity index) (7) were excluded from
randomization because greater tortuosity and angulation
impaired the effectiveness of using a distal ANGIO-
GUARD CPD as well as increased complications (8).
During the randomization period, 250 carotid stenting
procedures were performed at our institution, and 67 pa-
tients met the inclusion/exclusion criteria and were enrolled
in the study. During the study, 2 patients withdrew their
consent to participate in the study, and in 5 patients at the
time of the procedure, the operators deemed their anatomy
more suitable for 1 or the other CPD, violating the in-
clusion criteria. These patients were excluded for the ﬁnal
analysis.
Randomization was performed before the beginning of the
procedure and done electronically using the complex samples
module of SPSS for Windows, version 19.0 (SPPS, Inc.,
Chicago, Illinois). Block randomization of 6 patients (3
patients for ANGIOGUARDand 3 patients forMo.Ma) was
used to ensure a periodic balance in the number of patients
assigned to each group.
The study protocol was in accordance with the Decla-
ration of Helsinki for human research and was approved
by the Ethics in Research Committee of our institution.
The entire supporting infrastructure for conducting the
research and monitoring the patients enrolled was offered
by the hospital, and all patients gave their written informed
consent. There was no sponsoring for this study.
CAS procedure. CAS was performed according to the service
routine, already described by Costa (9) and Cano (16) and
followed international guidelines (10,11). For uniformity of
the procedure, 1 type of carotid stent was used (PRECISE
PRO RX carotid stent, Cordis Bridgewater, New Jersey), the
same stent that was previously evaluated in the SAPPHIRE
(Stent and Angioplasty with Protection in Patients at High
Risk for Endarterectomy) trial (1). For the same reason, 1
type of distal CPD was chosen (ANGIOGUARD, Cordis).
At the time of recruitment, a single type of proximal CPD
was available for clinical use in our country (Mo.Ma, Invatec).
All patients were pre-medicated with clopidogrel 75
mg/day and aspirin 100 mg/day, at least 3 days before the
Table 1. Study Inclusion and Exclusion Criteria
Inclusion criteria
1. Male and female patients 40 years of age and older.
2. Asymptomatic patients with internal carotid artery stenosis 80% on angiography.
3. Symptomatic patients with internal carotid artery stenosis 50% on angiography.
4. Anatomic characteristics of the lesions that made it possible to use either type of cerebral protective device (proximal or distal).
5. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved
by the appropriate Medical Ethics Committee, Institutional Review Board, or Human Research Ethics Committee.
Exclusion criteria
1. Extensive ipsilateral or disabling stroke.
2. Ischemic ipsilateral stroke progressing to hemorrhagic within 60 days.
3. Decreased brain reserve deﬁned as extensive previous stroke, dementia, multiple lacunar infarcts.
4. Severe common carotid or intracranial artery lesion.
5. Occlusion of ipsilateral external carotid artery.
6. Occlusion of the target vessel occurred after indication of carotid artery stenting.
7. Occlusion of contralateral carotid artery.
8. Severe or obstructive lesion in vertebrobasilar segments.
9. Extremely calciﬁed aortic arc that compromised the origin of the common carotid artery or the brachiocephalic trunk.
10. Chronic or paroxysmal atrial ﬁbrillation treated with oral anticoagulation.
11. Acute coronary syndrome in the 30-day period before the procedure.
12. Contraindication to magnetic resonance examination (e.g., claustrophobia, pacemaker).
13. Patient has a history of bleeding diathesis within 1 month or coagulopathy or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated.
14. Patient has a known hypersensitivity or contraindication to aspirin, heparin, and clopidogrel/ticlopidine, stent, and/or contrast sensitivity/allergy that cannot be adequately
pre-medicated.
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1205intervention. Clopidogrel was continued for at least 1 month
after CAS and aspirin indeﬁnitely. Betablockers were dis-
continued at least 24 h before the procedure and other
medications used were at the discretion of the referring
physician.
Cerebral DW-MRI was performed before and 48 h after
CAS on 3-T unit (Excite HD, GE Medical Systems,
Milwaukee, Wisconsin) with a head coil of 8 channels. All
imaging was performed at the Hospital do Coração and
analyzed by an independent neuroradiologist blinded to the
CPD used.
Study endpoints. The primary endpoint of this study was
comparison of the incidence, number, size, and location of
new cerebral ischemic lesions using DW-MRI in patients
treated with a distal (ANGIOGUARD) versus a proximal
(Mo.Ma) CPD. Secondary endpoints included device
success rate and the rate of major clinical events (death,
major stroke, and myocardial infarction) up to 1 year.
Study deﬁnitions. Patients were considered symptomatic if
they had an ipsilateral neurological ischemic event within
180 days before the procedure. The procedure was consid-
ered successful when residual stenosis after CAS was 30%
without neurological complications. The ischemic lesions
were considered ipsilateral when they occurred in the
hemisphere supplied by the target vessel; otherwise they
were contralateral. A transient ischemic attack was deﬁned
as a temporary alteration of the blood supply to an area of
the brain, resulting in a sudden and brief (<24 h, usually <1
h) decrease in brain function. Symptoms varied dependingon the area of the brain affected (12). Stroke was deﬁned as
a new focal neurological deﬁcit with symptoms and signs
consistent with focal ischemia lasting >24 h with the deﬁcit
corresponding to a vascular territory. The modiﬁed Rankin
Scale score >2 was used to deﬁne classiﬁcation as major and
as minor when the score was 2. A minor stroke causes
a neurological deﬁcit that resolves completely within 30
days, whereas a major stroke causes a neurological deﬁcit
that does not resolve completely within 30 days and leads to
a worsening of performance of daily activities (13,14).
Statistical analysis. Categorical variables were presented as
frequency and percentage and quantitative variables were
summarized as mean and SD, when normally distributed, or
as median and interquartile range otherwise. The groups
were compared using the Student t or Mann-Whitney
test and the Pearson chi-square or Fisher exact test for
numerical and categorical variables, respectively. To control
the inﬂuence of confounding factors on the presence of new
cerebral ischemic lesions, we used 2 approaches: conven-
tional covariance analysis by simple and multiple logistic
regression models (univariate and multivariate) (15) and
propensity scores (16).
The multivariate model included variables with p < 0.10
in the univariate analysis and those with signiﬁcant (or
marginal) differences between groups. The same variables
were selected for a logistic regression with group as
a dependent variable to estimate the probability that
a patient would be assigned to the ANGIOGUARD or
Mo.Ma CPD. Inverse estimated probabilities (propensity
Table 2. Baseline Clinical and Angiographic Characteristics
Cerebral Protection
p Value
ANGIOGUARD
(n ¼ 30)
Mo.Ma
(n ¼ 30)
Men 19 (63.3) 21 (70.0) 0.584
Age, yrs 68.5  7.5 67.0  9.3 0.493
Age 80 yrs 2 (6.7) 1 (3.3) >0.999
Symptomatic 6 (20.0) 9 (30.0) 0.371
Previous carotid disease* 15 (50.0) 19 (63.3) 0.297
Hypertension 28 (93.3) 28 (93.3) >0.999
CAD 24 (80.0) 18 (60.0) 0.158
Dyslipidemia 24 (80.0) 23 (76.7) 0.754
Diabetes mellitus 12 (40.0) 12 (40.0) >0.999
Peripheral vascular disease 11 (36.7) 18 (60.0) 0.071
COPD 2 (6.7) 2 (6.7) >0.999
Chronic renal insufﬁciency 4 (13.3) 8 (26.7) 0.197
Aortic arch classiﬁcation, type 0.437
I 19 (63.3) 17 (56.7)
II 5 (16.7) 9 (30.0)
III 6 (20.0) 4 (13.3)
Aortic characteristics
Calciﬁed 8 (26.7) 3 (10.0) 0.095
Elongated 1 (3.3) 1 (3.3) >0.999
Bovine arch 2 (6.7) 4 (13.3) 0.671
Contralateral lesion or
previous stent
11 (36.7) 11 (36.7) >0.999
Characteristics of treated lesion
Localization 0.472
Carotid bifurcation 24 (80.0) 27 (90.0)
Distal to bifurcation 6 (20.0) 3 (10.0)
Plaque characteristics 0.791
Regular 19 (63.3) 18 (60.0)
Irregular 11 (36.7) 12 (40.0)
Degree of calciﬁcation 0.004
Absent or very little 5 (16.7) 17 (56.7)
Moderate 10 (33.3) 7 (23.3)
Severe 15 (50.0) 6 (20.0)
Tortuosities 0.511
Absent 13 (43.3) 18 (60.0)
Proximal 1 (3.3) 2 (6.7)
Middle 6 (20.0) 3 (10.0)
Distal 10 (33.3) 7 (23.3)
Ulcerated 3 (10.0) 1 (3.3) 0.612
Eccentric 22 (73.3) 23 (76.7) 0.766
Stenosis, % 82.8  5.4 84.4  7.0 0.327
Lesion length, mm 13.1  8.6 14.6  9.3 0.537
Collateral contralateral circulation 22 (73.3) 15 (50.0) 0.063
Middle cerebral artery 30 (100) 30 (100) N/A
Anterior cerebral artery 24 (80.0) 18 (60.0) 0.091
Values are n (%) or median  SD. *Transient ischemic attack or stroke >180 days.
CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; N/A ¼ not
applicable.
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1206scores) were used as individual weights in a weighted
logistic regression model. Alternatively, the propensity score
was included as a covariate in the unadjusted regression
model.
For the number of new ischemic lesions (total and ipsi-
lateral), we used the Poisson regression model (17). The
propensity score approach (as a weighted model or as a co-
variate) was also applied.
The level of signiﬁcance was p ¼ 0.05. The statistical
programs used were SPSS for Windows, version 19.0
(SPPS, Inc., Chicago, Illinois) and R software version 16.0
(R Foundation for Statistical Computing, Vienna, Austria).
Results
Between July 2008 and July 2011, 60 patients were
randomized to receive either an ANGIOGUARD or
Mo.Ma CPD.
Clinical and angiographic characteristics of the enrolled
patients are summarized in Table 2. The majority of patients
were male (67%), and >20% in both groups had undergone
a previous carotid intervention (7 [23%] patients in the
ANGIOGUARD group vs. 6 [20%] in the Mo.Ma group,
p ¼ 0.753). Most previous carotid interventions (12 of 13)
were performed in the contralateral carotid artery. Also,
previous coronary revascularization was performed in 25%
of the total number of study patients with no signiﬁcant
difference between groups (30% of the patients with
distal CPD vs. 20% of the patients with proximal CPD
[p ¼ 0.371]).
The groups were also similar with regard to the lesion
characteristics, except for the amount of calciﬁed lesions,
which were more prevalent in the ANGIOGUARD cohort
(p ¼ 0.004). Of the total study population, 22 (36.7%)
patients had bilateral carotid lesions, equally divided in both
groups.
DW-MRI performed before the procedure found no
difference between the groups with regard to cerebral
atrophy, leukoaraiosis, or the presence of previous cerebral
microinfarction (Table 3).
The number of old infarcts per patient ranged from 1 to 9
in the ANGIOGUARD group and from 1 to 7 in the
Mo.Ma group. Regarding the size of the old infarcts, most
were <1.5 cm (90.5% in ANGIOGUARD and 74.4% in
Mo.Ma). All 15 patients with a previous stroke (7 Mo.Ma, 8
ANGIOGUARD) were classiﬁed according to both modi-
ﬁed Rankin Scale score and Barthel Index of Activities of
Daily Living score, and most of them had no signiﬁcant
disability and were able to carry out all usual activities, with
a modiﬁed Rankin Scale score between 0 and 1, and in ﬁve
patients a score of 2; the Barthel Index score of all 15
patients was 100 points before CAS.
Only 1 patient in the ANGIOGUARD group and 2 in
the Mo.Ma cohort had acute hyperintense Cerebral images
Table 3. Diffusion-Weighted Magnetic Resonance Imaging
Before Carotid Artery Stenting
Cerebral Protection
p Value
ANGIOGUARD
(n ¼ 30)
Mo.Ma
(n ¼ 30)
Cerebral atrophy
Absent 8 (26.7) 6 (20.0) 0.920
Minimum (sulci 3 mm) d d
Moderate (sulci >3 to 5 mm) 19 (63.3) 21 (70.0)
Intense (sulci >5 mm) 3 (10.0) 3 (10.0)
Leukoaraiosis
Absent/minimum, rare foci 22 (73.3) 22 (73.3) >0.999
Moderate, numerous foci but narrow 6 (20.0) 5 (16.7)
Severe, wide, and diffuse 2 (6.7) 3 (10.0)
Old infarction 14 (46.7) 13 (43.3) 0.795
New microinfarction 1 (3.3) 2 (6.7) >0.999
Microhemorrhages 14 (46.7) 14 (46.7) >0.999
Values n (%).
Table 4. Procedure Characteristics
Cerebral Protection
p Value
ANGIOGUARD
(n ¼ 30)
Mo.Ma
(n ¼ 30)
Treated artery
Right internal carotid artery 12 (40.0) 20 (66.7) 0.038
Left internal carotid artery 18 (60.0) 10 (33.3)
Duration of CAS, min 24.2 (10.4) 29.5 (10.3) 0.051
Total contrast, ml 97.5 (70–100) 80.0 (60–100) 0.319
Residual lesion 14 (0–20) 10.0 (0–17) 0.244
Values are n (%) or median (interquartile range).
CAS ¼ carotid artery stenting.
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1207on DW-MRI that probably occurred because of particles
released either during or after diagnostic carotid angiography
done a few days before CAS or spontaneously, although the
patients remained completely asymptomatic.
Carotid angioplasty results. Clinical and procedural
successes were achieved in 98.3% of the patients; 1 patient
experienced a minor stroke during the procedure. In all of
the patients, it was possible to complete CAS with the
CPD according to randomization. There was no cro-
ssover between groups. Despite randomization, in the
ANGIOGUARD group, a greater proportion of patients,
the left carotid artery was treated (60% vs. 33% in the
Mo.Ma group), with statistical signiﬁcance (p ¼ 0.038)
(Table 4).
The procedure duration tended to be longer in the
Mo.Ma group (29.5 min) compared with the distal CPD
cohort (D24.2 min, p ¼ 0.051).
There were no immediate deaths or major strokes. There
were a low incidence of other complications, such as hypo-
tension and bradycardia, and no statistical difference
between groups. One patient (1.66%) required vascular
surgery to stop bleeding at a puncture site. There was a late
retinal infarction in a patient in the ANGIOGUARD
group, and a patient with hyperperfusion syndrome in the
Mo.Ma group, both of whom recovered quickly.
Results of DW-MRI after CAS. The ﬁndings of DW-MRI
after CAS are shown in Table 5. The incidence of new
microischemic lesions did not differ between groups (63.3%
for the ANGIOGUARD group vs. 66.7% for the Mo.Ma
group, p ¼ 0.787).
CPD analysis according to the subgroups of interest did
not point to any signiﬁcant difference between the devices.
However, when the number of new lesions per patients was
analyzed, there was a statistically signiﬁcant associationbetween symptoms and the number of new lesions. Symp-
tomatic patients had a greater number of lesions, with a
signiﬁcant p value ¼ 0.001 for the whole group and for those
with a the ANGIOGUARD CPD, and less signiﬁcance
with the Mo.Ma CPD (p ¼ 0.039).
The majority of the new lesions were <0.5 cm, and
>70% of the lesions were in a cortical location. There were
no differences between groups with respect to lesion size
(p ¼ 0.950), anatomic location (p ¼ 0.360), and vascular
distribution (p ¼ 0.915).
The total number of lesions seen on DW-MRI was
signiﬁcantly higher among patients with a distal CPD (424
lesions/19 patients vs. 167 lesions/20 patients in the Mo.Ma
cohort, p < 0.001) as well as the number of lesions per
patient (a median of 10 in the distal CPD group vs.
a median of 6 in the proximal CPD group, p < 0.001).
Overall, most new lesions were ipsilateral (>90% in both
groups).
There were no independent predictors of acute ischemic
event among these patients, regardless of the statistical
model or correction (propensity score) applied.
Discussion
Our results showed that regardless of the CPD used during
CAS, new cerebral lesions developed in >60% of patients as
seen on DW-MRI, but the number of lesions per patient
was greater in the ANGIOGUARD group. Fortunately,
most DW-MRI–detected embolizations did not have
immediate clinical translation, even though the effect on
cognitive function is still debated (18). The majority of
lesions (>90%) were smaller (<0.5 mm). There was no
major stroke or death during hospitalization and at least
1 year of follow-up.
The recently published PROFI (Prevention of Cerebral
Embolization by Proximal Balloon Occlusion Compared to
Filter Protection During Carotid Artery Stenting) trial (19),
which also compared distal and proximal protection during
CAS (n ¼ 62), showed a higher incidence cerebral ischemic
Table 5. DW-MRI After Carotid Artery Stenting
Characteristics on DW-MRI
Cerebral Protection
p Value
ANGIOGUARD
(n ¼ 30)
Mo.Ma
(n ¼ 30)
Patients with new lesions 19 (63.3) 20 (66.7) 0.787
Patients with new ipsilateral lesions 17 (56.7) 19 (63.3) 0.598
Patients with new lesions >1 cm 3 (10.0) 2 (6.7) >0.999
Patients with new ipsilateral lesions >1 cm 2 (6.7) 2 (6.7) >0.999
Vascular distribution
Ipsilateral 17 (56.7) 19 (63.3) 0.598
Contralateral 11 (36.7) 8 (26.7) 0.405
Supratentorial vertebrobasilar 7 (23.3) 7 (23.3) >0.999
Infratentorial vertebrobasilar 3 (10.0) 2 (6.7) >0.999
No. of new lesions per patient* 10 (3–42) 6 (2–8) <0.001
Total no. of new lesions 424 (19p) 167 (20p)
No. of new ipsilateral lesions* 12 (3–41) 6 (1–8) <0.001
Total no. of new ipsilateral lesions 395 (17p) 145 (19p)
Values are n (%) or median (interquartile range). *Only patients with new lesions (excluding
those with no lesions).
DW-MRI ¼ diffusion-weighted magnetic resonance imaging; p ¼ patients.
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1208events after the use of a distal ﬁlter (87.1% vs. 45.2%, p ¼
0.001). Although in our study the number of ischemic events
was insufﬁcient to determine the difference between the
groups, the number of particles per patient undergoing
CAS was signiﬁcantly lower in the proximal CPD group
than in the distal CPD group (167 in 20 patients vs. 424 in
19 patients, respectively), which is in accordance with the
PROFI trial ﬁndings, which also pointed to a signiﬁcant
reduction in the incidence, number, and volume of new
cerebral ischemic lesions in patients who underwent CAS
with a proximal balloon as compared with distal (ﬁlter)
protection.
As previously demonstrated, microparticles embolized
during CAS might be generated during all of the steps of
the procedure. Montorsi et al. (20) compared the frequency
of microparticles generated during CAS with the proximal
Mo.Ma CPD and the distal FilterWire EZ Embolic
Protection System (Boston Scientiﬁc, Natick, Massachu-
setts) in lipid-rich atherosclerotic plaques by transcranial
Doppler imaging during the various phases of stenting: 1)
lesion wiring; 2) pre-dilation; 3) stent crossing; 4) stent
deployment; 5) stent dilation; and 6) device retrieval/
deﬂation. The authors reported fewer signals (microembolic
signals) detected by transcranial Doppler imaging in the
Mo.Ma group compared with FilterWire EZ Embolic
Protection System group in phases 3, 4, and 5 (27% vs.
100%, p < 0.0001) and higher in phase 6 (8.5% vs. 2%, p ¼
0.0036) with no difference in phase 2. Patients in the
Mo.Ma group had a decrease in the number of micro-
embolic signals compared with the FilterWire EZ, with
statistical signiﬁcance in patients with high-risk, lipid-rich
plaque undergoing CAS.In our study, ipsilateral lesions after CAS were observed
in 395 of 424 patients (93%) with the ANGIOGUARD
CPD and 145 of 167 patients (87%) with the Mo.Ma CPD.
The presence of ipsilateral lesions can be attributed to the
release of particles from the treated plaque during CAS.
Stojanov et al. (21) assessed the correlation between carotid
plaque composition and the risk of distal embolization
during CAS. They studied a group of 50 patients using
a distal CPD ﬁlter. Plaque morphology was differentiated
by sonography as ﬁbrolipid or ﬁbrocalciﬁc. They found
14.89% of new lesions on DW-MRI, 8.51% in the ipsilat-
eral territory, and those with ﬁbrolipid plaques had signiﬁ-
cantly more new lesions compared with ﬁbrocalciﬁc plaques
(p ¼ 0.041). The absolute risk of new lesions in the ﬁbro-
lipid group was 18.18%. Most of the patients with lesions
had no clinical symptoms, and no signiﬁcant relationship
was found between new lesions and factors related to CAS.
The source of contralateral lesions was described by
Barbato et al. (22), who showed that the occurrence of
microemboli during CAS was not prevented by the use of
distal ﬁlter, and in one ﬁfth of patients, embolization
occurred in the contralateral hemisphere. They found
a correlation between age, increasing amount of calcium in
the aortic arch, and the presence of aortic arch type II and
the occurrence of new lesions. Other previous studies have
also shown that both aortic arch anatomy and a tortuous
carotid artery proximal to a plaque signiﬁcantly increased the
risk of technical failure and neurological complications
during CAS (7,23).
Major technical and technological advances are taking
place with the introduction of appropriate dedicated stents,
better patient selection, improvement in physicians expertise
and new cerebral protection devices (24). Even though we
believe that CPDs have made a great contribution to the
development of carotid intervention, we cannot forget that
CAS still has the inherent risk of potential stroke.
Study limitations. The relatively small sample size might
preclude deﬁnite conclusions about the efﬁcacy of the tested
devices in this clinical scenario. Also, only 2 types of CPDs
were tested, and, therefore, the results do not apply to the
various proximal and distal CPDs currently available.
Conclusions
New ischemic lesions seen on DW-MRI were present
in >60% of both groups, but the number of lesions per
patient was greater in the ANGIOGUARD than in the
Mo.Ma cohort. There were no deaths or disabling strokes
in the one-year follow-up of the entire population.
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